Challenging Times for European Biotech IPOs

Through the first week of May, 2005, five biotechs listed on Europe's main markets. Like their counterparts in the US, these companies have had to deal with difficult public markets and have on the whole raised much less money than they originally intended.

European private investors are faring no better than their US counterparts when it comes to IPOs in 2005. Both sides of the Atlantic have been plagued by problematic public markets that have resulted in public offerings at or below estimated pricing ranges and difficult aftermarket environments. (See Exhibit 1.) So far this year five firms have hit Europe's main markets: Ardana Bioscience Ltd. on the London Stock Exchange [See Deal], Intercell AG in Vienna [See Deal], Paion AG in Frankfurt [See Deal], Arpida Ltd. on the Swiss Exchange [See Deal], and, most recently as of START-UP press time, Galapagos Genomics NV in Amsterdam and Brussels [See Deal]. Much like in the US, others including Scotland's Cyclacel Ltd. , have gotten cold feet and pulled their offerings [See Deal].

While US companies have traditionally enjoyed public market support unavailable to European companies, those days are seemingly gone. The wave...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.